ACRP CCRA Designation Recognized by TransCelerate Biopharma as Evidence of Good Clinical Practice Training - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
ACRP CCRA Designation Recognized by TransCelerate Biopharma as Evidence of Good Clinical Practice Training

Source: Company News Release

The Certified Clinical Research Associate (CCRA) designation is now formally recognized by TransCelerate Biopharma, Inc. (www.transceleratebiopharmainc.com) as evidence of Good Clinical Practice (GCP) training.

Clinical research professionals who hold a current CCRA designation may use that designation as evidence of GCP training while working at any of TransCelerate's 19 member companies, freeing them from any potential obligatory and/or redundant GCP training.

TransCelerate member companies include some of the world's largest pharmaceutical and biotechnology companies with research and development (R&D) operations, including Johnson & Johnson, AstraZeneca, Pfizer, Roche, GlaxoSmithKline, and more. TransCelerate launched in 2012 "to advance innovation in R&D, identify and solve common R&D challenges, and further improve patient safety."

"The CCRA designation shows both my employer and the sites I monitor that I have taken the extra step to be a professional," says Kathryn Kimmel, CCRA, CCRC, Senior Clinical Research Associate at PAREXEL International. "The CCRA designation states I have not only GCP training, but know International Conference on Harmonization and all standards that are needed for good clinical research to be performed at the site level and within my company. It establishes me as someone who has demonstrated the ability to apply this knowledge."

Recognition of the CCRA designation follows TransCelerate's January 2014 recognition of the Certified Clinical Research Coordinator (CCRC) and Certified Physician Investigator (CPI) designations as evidence of GCP training. In February 2014, TransCelerate also recognized ACRP GCP training courses as evidence of required GCP training.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here